Generate Biomedicines, Inc. (GENB) IPO - S-1 Filing, Stock & Insider Activity
Generate Biomedicines, Inc. IPO - Status & S-1 Filing
- Ticker: GENB
- Status: Priced - IPO complete
- S-1 filed: 2026-02-04
- Effective: 2026-02-26
- IPO / pricing date: 2026-02-27
- Exchange: NASDAQ
- Offering price: $16.00
- Shares offered: 25,000,000
- SEC CIK: 0002100782 · View the S-1 on SEC EDGAR →
Generate Biomedicines, Inc. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Generate Biomedicines, Inc. (GENB) - no SEC Form 4 insider filings recorded in the last 90 days. 1 Form 8-K material event filing was reported by GENB in the last 90 days. InsiderAlpha tracks every GENB SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. trades under the ticker GENB. InsiderAlpha tracks 15 primary SEC Form 4 filings from 14 reporting insiders for GENB since 2026, sourced directly from SEC EDGAR.
| SEC CIK | 0002100782 |
|---|
90-Day SEC Filing Activity
| Form 8-K filings (90d) | 1 |
|---|---|
| Latest Form 4 filing | 2026-03-06 |
Recent GENB Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Michael Nally | Chief Executive Officer | P - Open-market purchase | 20.0K | $12.00 | $240K | SEC | |
| Noubar Afeyan | Insider | J - Other acquisition / disposition | 13.70M | - | - | SEC | |
| Noubar Afeyan | Insider | J - Other acquisition / disposition | 987.5K | - | - | SEC | |
| Noubar Afeyan | Insider | J - Other acquisition / disposition | 2.78M | - | - | SEC | |
| Noubar Afeyan | Insider | J - Other acquisition / disposition | 2.78M | - | - | SEC | |
| Noubar Afeyan | Insider | P - Open-market purchase | 1.56M | $16.00 | $25.00M | SEC | |
| Noubar Afeyan | Insider | P - Open-market purchase | 1.56M | $16.00 | $25.00M | SEC | |
| Noubar Afeyan | Insider | P - Open-market purchase | 1.56M | $16.00 | $25.00M | SEC | |
| Noubar Afeyan | Insider | J - Other acquisition / disposition | 12.72M | - | - | SEC | |
| Jane L. Mendillo | Insider | P - Open-market purchase | 1.5K | $16.00 | $24K | SEC | |
| Beth Grous | Chief People Officer | P - Open-market purchase | 300 | $16.00 | $5K | SEC | |
| Jason Silvers | President & CFO | P - Open-market purchase | 500 | $16.00 | $8K | SEC | |
| Jason Silvers | President & CFO | P - Open-market purchase | 500 | $16.00 | $8K | SEC | |
| Jason Silvers | President & CFO | P - Open-market purchase | 1.0K | $16.00 | $16K | SEC | |
| Michael Nally | Chief Executive Officer | J - Other acquisition / disposition | 658.3K | - | - | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Generate Biomedicines, Inc. (GENB). Updated in real time as new filings are submitted to the SEC.
Recent GENB Form 8-K Material Events
- - Item 2.02, 9.01 [SEC]
Recent Insider Filings
- - Michael Nally (Chief Executive Officer)
- - Rupert Vessey (Insider)
- - Beth Grous (Chief People Officer)
- - Frances Arnold (Insider)
- - Laurie Anne Lee (Chief Medical Officer)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in GENB insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
GENB Insider Trading - FAQ
- What is the latest insider trade for GENB?
- Generate Biomedicines, Inc. (GENB) had 0 insider filings in the last 90 days, with the most recent on 2026-03-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying GENB stock?
- 0 insider purchases of GENB were filed in the last 90 days.
- How many insiders are selling GENB stock?
- 0 insider sales of GENB were filed in the last 90 days.
- Where can I see GENB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks GENB Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $GENN Genneia S.A.
- $GF NEW GERMANY FUND INC
- $GFLT GenFlat Holdings, Inc.
- $GHXI Gores Holdings XI, Inc.
- $GHYP Grayscale HYPE ETF
- $GITS Global Interactive Technologies, Inc.
- $GIVE Wealth Management System Inc.
- $GIX GigCapital9 Corp.
- $GLED GalaxyEdge Acquisition Corp
- $GLEI Galaxy Enterprises Inc. /WY/
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live GENB dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.